Pfizer Inc
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +5.3% | -2.4% | -2.2% | +1.5% | -2.8% | -2.5% | -0.9% | +1.3% | -0.3% | -0.3% | -3.1% | |
| – | -41.5% | -2.1% | -10.8% | +14.3% | +16.5% | -8.9% | -4.7% | +7.4% | -8.6% | -0.2% | -3.4% | |
| – | -9.4% | -74.8% | +46.3% | +3.8% | -4.5% | +37.1% | +14.5% | -18.0% | -15.0% | +49.1% | -42.7% | |
| – | -71.3% | -6.0% | -40.5% | +40.1% | +105.8% | -15.4% | -23.5% | +13.1% | -9.3% | -3.8% | -10.5% | |
| – | -25.5% | -1.7% | +37.3% | +17.3% | -16.5% | -0.2% | +9.1% | +12.6% | -12.6% | -20.6% | -0.8% | |
| – | -0.1% | +6.9% | +5.1% | +2.4% | -7.4% | +0.0% | +7.5% | -1.7% | -7.1% | +0.1% | -6.8% | |
| – | +22.4% | -14.0% | – | – | -0.8% | -0.3% | +2.3% | +0.6% | +2.3% | – | – | |
| – | +31.5% | +2.2% | -1.2% | +0.2% | -0.1% | -0.1% | +0.8% | +0.2% | +3.1% | +0.2% | +0.0% | |
| – | +61.3% | -3.2% | -2.5% | -2.0% | -7.6% | -2.6% | -2.4% | -2.6% | +4.7% | -2.2% | -10.5% | |
| – | +16.5% | -6.3% | -0.2% | -1.0% | -1.6% | -6.0% | -0.3% | -1.2% | +5.0% | -3.4% | -1.3% | |
| – | +53.5% | -15.3% | +8.2% | -1.4% | -0.5% | -15.2% | +3.5% | -3.0% | +1.1% | -7.1% | -5.0% | |
| – | +326.9% | -24.3% | +45.1% | -18.8% | -28.4% | -35.6% | -3.9% | +0.2% | -19.0% | +11.7% | -30.6% | |
| – | +25.7% | -16.7% | -8.7% | +4.1% | +6.0% | -7.0% | -1.4% | -2.7% | +4.3% | -14.0% | +1.7% | |
| – | -0.1% | -0.1% | -6.9% | +0.3% | -0.4% | +0.2% | -0.3% | -0.2% | +7.5% | -1.6% | +1.1% | |
| – | -8.2% | +3.7% | -5.0% | +5.2% | -4.4% | +2.4% | -1.8% | +4.6% | -6.8% | +4.2% | -5.5% | |
| – | -6.4% | +2.5% | -3.9% | +3.8% | -3.6% | +2.5% | -1.7% | +3.0% | -5.4% | +2.3% | -4.4% | |
| – | +0.0% | +0.9% | 0.0% | +0.2% | 0.0% | +0.1% | -0.1% | +0.1% | -0.5% | +0.8% | -0.6% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.